Compare APMD & SMBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APMD | SMBK |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 895.5M | 871.9M |
| IPO Year | 2026 | 2000 |
| Metric | APMD | SMBK |
|---|---|---|
| Price | $18.65 | $48.95 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | $50.33 | ★ $52.88 |
| AVG Volume (30 Days) | ★ 380.6K | 104.7K |
| Earning Date | 11-03-2026 | 10-19-2026 |
| Dividend Yield | N/A | ★ 0.73% |
| EPS Growth | N/A | ★ 39.25 |
| EPS | N/A | ★ 1.77 |
| Revenue | N/A | N/A |
| Revenue This Year | $136.17 | $12.42 |
| Revenue Next Year | N/A | $9.45 |
| P/E Ratio | ★ N/A | $27.82 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.43 | $34.23 |
| 52 Week High | $35.29 | $54.14 |
| Indicator | APMD | SMBK |
|---|---|---|
| Relative Strength Index (RSI) | 42.47 | 40.25 |
| Support Level | $17.38 | $40.28 |
| Resistance Level | $20.00 | $49.07 |
| Average True Range (ATR) | 1.62 | 1.32 |
| MACD | 0.22 | -0.13 |
| Stochastic Oscillator | 41.02 | 25.65 |
Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).
SmartFinancial Inc operates as a bank holding company for SmartBank. It offers various banking and financial services to individuals and corporate customers. The principal business of the Bank consists of attracting deposits from the general public and investing those funds, together with funds generated from operations and from principal and interest payments on loans, mainly in commercial loans, commercial and residential real estate loans, consumer loans, and residential and commercial construction loans. The primary source of revenue is interest income from earning assets, namely loans and securities.